Gynecology & Obstetrics
Open Access
ISSN: 2161-0932
ISSN: 2161-0932
Unidad de Medicina Materno Fetal Perinatal Care IPS. Servicio de Ginecología y Obstetricia, Clínica , Departamento de Ginecología y Obstetricia, Fundación Universitaria Autónoma de las Américas, Pereira (Colombia)., Unidad de Medicina Materno Fetal Perinatal Care IPS. Servicio de Ginecología y Obstetricia, Clínica San Rafael. Departamento de Ginecología y Obstetricia, Fundación Universitaria Autónoma de las Américas, Pereira, Colombia
Research Article
Author(s): Saulo Molina-Giraldo, Issis judith Villa-Villa, Roberto Zapata, Mauricio Orozco, Nataly VelásquezMuñoz, Diana Alfonso, Wilma Castilla-Puentes, Jose Luis Pérez, Oscar Ordoñez, Oscar Zuluaga, Jesús Andrés Benavides-Serralde, Carol Gisela Rueda-Ordoñez, Armicson Felipe Solano and Juan Pablo Alzate-Granados
Introduction: Preeclampsia is a multisystemic disease of pregnancy. Prevention of the disease has been a concern of health care models and more so of those that include pathology in which there is a compromise of the perinatal maternal outcome. It has been described that ASA (a cyclooxygenase inhibitor with anti-inflammatory and antiplatelet properties) could have an impact on the prevention of this disease. The purpose of this consensus is to summarize the evidence and provide current recommendations on the use of ASA in the prevention of preeclampsia.
Methods: FECOPEN convened a national meeting of experts to create a non-formal consensus based on a review of the literature with the elaboration of a questionnaire with relevant questions to provide current recommendations on the use of ASA for the prevention of preeclampsia.
Results: A questionnaire of 30 question.. View More»